SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. (opens ClinicalTrials.gov)
- Sponsor
- Ministry of Health, Saudi Arabia
- Enrolment
- 240
- Started
- 2027-01-01
- Last update
- 2026-05-29
Conditions: Type 1 Diabetes Mellitus
Interventions: Recombinant Zoster Vaccine (Shingrix; RZV), Semaglutide (Ozempic®), Placebo (saline injection)